Healthcare providers with PAH patients who are taking Tyvaso® and using the Tyvaso Inhalation System have a wide range of resources and
support services available to them.
Living PAH is a comprehensive support program for patients on United Therapeutics therapies. The program is dedicated to improving the lives of
PAH patients by providing them with FREE information and personalized support to encourage treatment adherence and help them cope with their disease.
Living PAH Is Here for Your Patients
Living PAH is here to support your patients. Check out the following resources Living PAH has available:
Disease education Patients can enhance their understanding of PAH and its treatment through patient-friendly materials
Regional education events Patients can participate in discussions in which healthcare professionals present
information on topics of interest to patients
Emotional support Patients can establish ongoing relationships with patient mentors
Treatment support services Based on their individual needs, patients will receive customized materials to help them
stay on track with their medications
It's FREE! Enrollment gives access to:
PEER Network Talk one-on-one with another PAH patient through secure, confidential phone calls or emails
Patient PHorums Attend informational seminars to learn about PAH and various treatment options, and connect with a community
of people near you who are living with PAH
Patient Call Center The Living PAH Call Center operates 24 hours a day, 7 days a week. Operators are on hand
from 7:00 a.m. to 7:00 p.m. The Patient Call Center number is 1-877-948-9137
Selected Important Safety Information
The most common adverse events seen with Tyvaso in ≥4% of PAH patients and more than 3% greater than placebo in the placebo-controlled clinical study were cough (54% vs 29%), headache (41% vs 23%), throat irritation/pharyngolaryngeal pain (25% vs 14%), nausea (19% vs 11%), flushing (15% vs <1%), and syncope (6% vs <1%)
Tyvaso should be used in pregnancy only if clearly needed. Caution should be exercised when Tyvaso is administered to nursing women
Indication
Tyvaso is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%).
The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities.
While there are long-term data on use of treprostinil by other routes of administration, nearly all controlled clinical experience with inhaled treprostinil has been on a background of bosentan (an endothelin receptor antagonist) or sildenafil (a phosphodiesterase type 5 inhibitor). The controlled clinical experience was limited to 12 weeks in duration.
Important Safety Information for Tyvaso
Tyvaso is intended for oral inhalation only. Tyvaso is approved for use only with the Tyvaso Inhalation System
The safety and efficacy of Tyvaso have not been established in patients with significant underlying lung disease (such as asthma or chronic obstructive pulmonary disease) and in patients under 18 years of age. Patients with acute pulmonary infections should be carefully monitored to detect any worsening of lung disease and loss of drug effect
Tyvaso may increase the risk of bleeding, particularly in patients receiving anticoagulants
In patients with low systemic arterial pressure, Tyvaso may cause symptomatic hypotension. The concomitant use of Tyvaso with diuretics, antihypertensives, or other vasodilators may increase the risk of symptomatic hypotension
Hepatic or renal insufficiency may increase exposure to Tyvaso and decrease tolerability. Tyvaso dosage adjustments may be necessary if inhibitors of CYP2C8 such as gemfibrozil or inducers such as rifampin are added or withdrawn
The most common adverse events seen with Tyvaso in ≥4% of PAH patients and more than 3% greater than placebo in the placebo-controlled clinical study were cough (54% vs 29%), headache (41% vs 23%), throat irritation/pharyngolaryngeal pain (25% vs 14%), nausea (19% vs 11%), flushing (15% vs <1%), and syncope (6% vs <1%)
Tyvaso should be used in pregnancy only if clearly needed. Caution should be exercised when Tyvaso is administered to nursing women
The content of the linked site is the sole responsibility of the site provider. United Therapeutics Corporation does not control or endorse this third-party site.
Click "CONTINUE" to proceed or "RETURN" to return to TYVASO.com
Why
